Propylene Glycol-Free melphalan HCL for Injection (PGF-Mel) is a new formulation that incorporates Captisol, a specially modified cyclodextrin, to improve melphalan stability. In this phase IIa, open-label, randomized, cross-over design bioequivalence study, the pharmacokinetics of PGF-Mel were compared with the marketed formulation of melphalan, or Alkeran. Patients received half of the total dose of melphalan in the form of Alkeran and the other half in the form of PGF-Mel in an alternating manner. The pharmacokinetic measures were determined using WinNonlin 6.2 and bioequivalence was assessed using log-transformed systemic exposure parameters. Twenty-four patients, 11 females and 13 males, were enrolled between 4 February 2010 and 16 May 2011 at The University of Kansas Medical Center and The University of Kansas Cancer Center. The median age of enrolled subjects was 58 years (range: 48-65). All patients achieved myeloablation 3 days post autologous graft followed by successful neutrophil engraftment with a median of 11 days after transplant. Pharmacokinetic analysis showed that PGF-Mel was bioequivalent with Alkeran and also revealed that maximum plasma concentration (C max ) and area under the plasma concentration − time curve (AUC) were higher (~10%) after PGF-Mel administration. In conclusion, PGF-Mel is considered bioequivalent to Alkeran while also demonstrating a marginally higher systemic drug exposure.
INTRODUCTION
High-dose chemotherapy and autologous transplantation is considered a standard care procedure in symptomatic, transplant eligible multiple myeloma (MM) patients. 1 The chemotherapy of choice is high-dose melphalan based on randomized clinical trials. 2, 3 Melphalan has marginal solubility and limited chemical stability upon reconstitution and dilution. Propylene glycol, used as a solubilizer in Alkeran (brand name melphalan) for Injection (Alkeran), can potentially contribute to an array of side effects. Side effects reported for products utilizing large amounts of propylene glycol include renal dysfunction, cardiac arrhythmias, hyperosmolality, increased anion gap metabolic acidosis, and sepsis-like syndrome. 4−6 LGD-353 or Propylene Glycol-Free Melphalan HCL for Injection (PGF-Mel) is a propylene glycol-free reformulation of Alkeran. PGF-Mel incorporates the Captisol brand of β-cyclodextrin sulfobutyl ethers sodium salts ([SBE] 7 m -β-CD). Captisol is also incorporated into other intravenously administered medications like voriconazole (VFEND I.V.), amiodarone (NEXTERONE Premixed Injection) and the recently approved carfilzomib (Kyprolis for Injection). In this study the primary endpoint was to assess whether PGF-Mel was bioequivalent to Alkeran using a randomized cross-over design. Other endpoints were to assess the efficacy of PGF-Mel and Alkeran in achieving myeloablation, and the safety and tolerability of PGF-Mel in comparison to Alkeran.
PATIENTS AND METHODS
This is a Phase IIa, open-label, randomized, cross-over design study where PGF-Mel and Alkeran were assessed in the same MM patients undergoing transplantation. Transplant candidate patients with symptomatic de novo or relapsed MM were included if they were 70 years of age or younger and if they demonstrated adequate organ function. Patients with stage 1 MM, history of more than one autologous stem cell transplant, plasma cell leukemia, systemic amyloid light-chain (AL) amyloidosis and/or Eastern Cooperative Oncology Group (ECOG) performance status ⩾ 2 were excluded. Patients with active bacterial, viral or fungal infection and those with prior malignancies were also excluded.
Pharmacokinetic levels were drawn just before chemotherapy infusion and at 10 post-dose time points up to 8 h after the end of the PGF-Mel and Alkeran infusions. Plasma levels of melphalan were determined by a sensitive liquid chromatography tandem mass spectrometry method. 7 The pharmacokinetic measures were determined using WinNonlin 6.2. Analysis of the log-transformed systemic exposure parameters (that is, C max and area under the curve (AUC) measures) was used to evaluate bioequivalence. Rates of myeloablation and subsequent engraftment were determined (definitions in subsequent paragraph). Safety and tolerability owing to half the administered dose coming from high-dose PGF-Mel was assessed in treated patients and toxicity was assessed according to NCI CTCAE version 3.0. Starting on Day +5, granulocyte CSF was administered at a dose of 5 μg/kg per day subcutaneously until ANC is 4500 mm 3 for 2 days. Patients were treated either as inpatients or outpatients and all were followed up until 7 days following engraftment. All patients were informed of the investigational nature of the study; all of them signed the written informed consent and they were given a copy of the same in accordance with the institutional and federal guidelines. This study was approved by the University of Kansas Medical Center's Institutional Review Board and was registered on ClinicalTrials.gov, identification number: NCT00925782.
Statistical analysis
Descriptive statistics were used to refer to the number of patients (n), mean, median, standard deviation, minimum, and maximum for continuous data and frequencies, and percentages for categorical data. Pharmacokinetic similarity was defined as a difference of 20% or less in 90% confidence intervals (CIs) for the ratios of the pharmacokinetic parameters (calculated using log-transformed data) for the two formulations. The analysis of variance model was to be used, adjusted for expected sources of variation typically observed in this study design. All statistical analyses were conducted with a significance level of 0.05 and utilized twosided testing. Statistical analysis was conducted using SAS v9.2 software (SAS Institute Inc., Cary, NC, USA).
Definitions
Myeloablation was defined as ANC below 500/μL, or absolute lymphocyte count below 100/μL or platelet count below 20 000/mm 3 . Neutrophil engraftment was defined as the first day of 3 consecutive days where ANC was higher than 500/μL following their nadir.
RESULTS

Patient characteristics
A total of 40 patients were screened and 24 patients were enrolled. All 24 patients received both formulations of melphalan (Alkeran and PGF-Mel) and no patients discontinued prematurely in this study. The study population consisted of 13 males (54%) and 11 females (46%) and the majority of patients (79%) were Caucasian. The median (range) age was 58 (48-65). All patients enrolled presented with MM and 62.5% had stage III disease. The mean (standard deviation) number of years since initial diagnosis was 1.6 (1.85) years. All patients had ECOG 0 or 1 performance status with 50% of patients having normal (ECOG = 0) performance status. Table 1 summarizes patient characteristics.
Efficacy data Efficacy was assessed in this study by determining rates and timing of myeloablation and engraftment. All patients achieved myeloablation with a median time of 3 days post graft and all successfully achieved neutrophil engraftment with a median time of 11 days post graft. There were no differences in the median times of myeloablation or engraftment if Alkeran was given first or PGF-Mel was given first.
Safety results
All 24 patients in the study received both formulations of melphalan (PGF-Mel and Alkeran or generic melphalan in 1 patient) each at a dose of 100 mg/m 2 (based on actual or ideal body weight). The duration of infusion of the melphalan doses varied between 28 and 44 min with mean infusion times of 32.1 and 32.6 min for the Alkeran and PGF-Mel infusions, respectively.
Treatment-emergent adverse events (TEAE) All patients in the study reported at least 1 TEAE during the study period (day − 3 to day 0) or during the follow-up period (day 1 to end of study). Individual TEAEs that were reported in ⩾ 50% of patients were nausea (100%), diarrhea (96%), vomiting and hypokalemia (88%), fatigue (83%), and thrombocytopenia (75%) decreased appetite and dizziness (63%), and the most frequently reported TEAEs during the study period included fatigue (63%), nausea (58%) and hypokalemia (46%). During the study period, the following adverse events occurred more frequently (⩾2 patient difference) when Alkeran was given first (nausea (8 patients vs 6 patients), fluid retention (5 patients vs 3 patients)) edema (4 patients vs 2 patients), headache and constipation (3 patients vs 1 patient), and taste changes, rash, and left bundle branch block (2 patients vs 0 patients)), while the following adverse events occurred more frequently (⩾2 patient difference) when PGF-Mel was given first (dizziness (4 patients vs 1 patient)).
Grade 3-4 TEAEs were reported in 17 (71%) patients. The most frequently reported grade 3 TEAEs were fatigue (7 patients), anemia (7 patients), febrile neutropenia (6 patients), mucositis (4 patients), nausea, diarrhea and hypokalemia (3 patients each). The only grade 4 TEAEs reported were thrombocytopenia (12 patients), leukopenia (3 patients), lymphopenia, neutropenia, hypophosphatemia and sepsis (1 patient each). Most grade 3-4 TEAEs were considered at least possibly related to treatment.
A total of seven (29%) patients reported treatment-emergent serious adverse events (SAEs) and all serious adverse events resulted in hospitalization (SAEs are summarized in Table 2 ). With the exception of 1 SAE for left bundle branch block, which was considered unrelated to study treatment, all SAEs were considered related to study treatment. The SAE for left bundle branch block was reported on the second dosing day prior to receiving the PGF-Mel treatment while the other SAEs occurred during the follow-up period (day 4 to day 11). These SAEs were for events of febrile neutropenia, mucositis, sepsis or extreme fatigue. All SAEs resolved with supportive care measures.
Vital sign changes Vital sign data that showed clinically insignificant small decreases from baseline values were evident for systolic blood pressure, diastolic blood pressure and respiration rate at most post-dose time points after administration of PGF-Mel while small mean increases from baseline values for these parameters were evident after Alkeran administration on the first dosing day (Day − 2).
Electrocardiogram (ECG) changes
Two patients receiving Alkeran on the first day of dosing exhibited abnormal clinically significant ECGs at the Day − 2, 2 h post-dose ECG. Both patients had prolonged QRS intervals (137 and 130 ms) and 1 of these events resulted in overnight hospitalization for observation. Both events resolved within 1 to 2 days with no treatment. In both cases the patients continued on the study. The 1 patient who was hospitalized for the left bundle branch block also experienced a prolonged QTc interval (518 ms) at the end of study visit. No other patients exhibited QTc intervals 4500 ms.
Pharmacokinetic results
Based on the noncompartmental analysis, the geometric mean ratios for the model-estimated C max , AUC 0-∞ and AUC 0-t were 112.00, 110.90 and 110.77%, respectively, and the associated 90% confidence intervals were contained within 80.00-125.00%, demonstrating bioequivalence based on these parameters. As a consequence of not collecting the blood sample at the end of the infusion, C max and AUC 0-∞ were underestimated using a noncompartmental model. Additionally, there was variation in the duration of the infusion time (28-44 min with a mean of 32 min) specified in the protocol (30 min). Thus, a compartmental analysis was undertaken to confirm the results of the statistical comparisons based on the parameters estimated by noncompartmental analysis. The plasma melphalan concentration-time data after IV administration of both formulations was well-described by a 2-compartment IV infusion model. As expected, the mean values for C max and AUC 0-∞ were higher (~35 and~20%, respectively) for the compartmental compared with the noncompartmental analysis. While there were small numerical differences in the geometric mean ratios and associated 90% confidence intervals, the latter were contained within 80.00-125.00% for both analyses. The compartmental analysis, therefore, confirmed the conclusions of bioequivalence from the noncompartmental analysis. Additionally, PGF-Mel resulted in marginally, but statistically significant, higher systemic drug levels than Alkeran (~110%) (Po 0.05). Figure 1 represents a plot of mean melphalan plasma concentration following PGF-Mel and Alkeran.
DISCUSSION
In this study, it was clearly demonstrated that PGF-Mel was bioequivalent to Alkeran. Moreover, PGF-Mel resulted in marginally higher systemic drug levels than Alkeran. The absence of propylene glycol and these findings make PGF-Mel a more attractive option than other melphalan formulations for high-dose therapy and transplant purposes. In addition, PGF-Mel is more stable following reconstitution, which eliminates the time constraints that are imposed on pharmacists and nursing staff when preparing high-dose Alkeran for infusion. These timing issues might result in delivery of a less than intended dose of high-dose melphalan at time of transplant, which results in effective-dose variability between patients. In the cross-over design utilized, the relative contribution of each of the interventions to efficacy and toxicity cannot be well-defined. Accordingly, we cannot determine the relative contribution of PGF-Mel to some end points in this study. For example, this study showed that all patients treated achieved successful myeloablation and subsequent engraftment with no evidence of graft failure. The relative contribution of PGF-Mel to myeloablation cannot be determined. In addition, toxicities reported with the exception of ECG changes, are all expected in patients who receive myeloablative therapy 8 and the relative contribution of PGF-Mel to these toxicities is currently unknown. The efficacy and toxicity solely related to PGF-Mel will be addressed in the ongoing phase IIb study.
PGF-Mel could potentially enable safe administration of higher doses of melphalan, which might lead to better myeloma responses. This is expected because response to high-dose therapy is dose dependent and has a linear, steep dose-response curve. 9 However, with increasing melphalan dose at time of transplant, nonhematologic toxicities like mucositis and atrial fibrillation remain a major concern.
Would the use of PGF-Mel reduce the risk of atrial fibrillation in the setting of high-dose melphalan therapy? Administration of higher doses of Alkeran in a short time, as typically done in transplant, can potentially lead to more infusion-related complications attributed to the propylene glycol present in Alkeran. One of these complications is cardiac arrhythmias. For example, atrial fibrillation has been reported to occur following high-dose melphalan therapy. 10, 11 In the current study, none of the treated patients developed atrial fibrillation. However, in this study, two patients developed left bundle branch block following Alkeran. These two patients subsequently received PGF-Mel without further complications and with resolution of left bundle branch block pattern. The ECG changes reported in this study were asymptomatic, but could have triggered symptomatic ECG changes if the patients received additional Alkeran doses. ECGs are not routinely performed in patients undergoing high-dose melphalan therapy and are usually performed when patients develop signs and symptoms related to these arrhythmias, which might explain why some of these changes are not well-reported in the literature.
PGF-Mel might also be considered in situations where Alkeran is associated with suspected infusion reactions. For example, in amyloidosis, the use of high-dose melphalan has been associated with increased renal failure rates. In one study, where acute renal insufficiency was defined as a minimum increase of 0.5 mg/dL (44 μmol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning, 18.8% of 80 evaluable patients developed acute renal insufficiency. 12 In this study, Alkeran was considered to be -the suspect in the setting of disease-related tubular injury. Alternatively, it could have been the propylene glycol component of high-dose melphalan that caused acute renal insufficiency in these patients as it has been linked to proximal renal tubular injury in some studies. 13 Accordingly, PGFMel might be a better option for patients with amyloidosis who undergo high-dose melphalan therapy.
In conclusion, PGF-Mel was shown to be bioequivalent to Alkeran for Injection. Based on the overall results of this study, the efficacy (myeloablation and engraftment) and safety profile were consistent with those already established for high-dose melphalan when given as a conditioning regimen with auto-SCT in MM patients.
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